TAGSS Pyloroplasty
Gastroparesis
Pre-clinicalActive
Key Facts
About Endo-TAGSS
Endo-TAGSS is a private, pre-revenue medical device company founded in 2016 and based in San Diego, CA, USA. Its core technology is the TAGSS device, a 12mm trans-abdominal gastric port system intended to bridge the gap between endoscopy and laparoscopy, allowing for more complex intragastric surgeries with fewer incisions and potentially lower costs. The company is in the pre-clinical stage, having demonstrated proof-of-concept in animal models for applications like pyloroplasty and fundoplication, but its devices are not yet FDA-cleared for sale.
View full company profileTherapeutic Areas
Other Gastroparesis Drugs
| Drug | Company | Phase |
|---|---|---|
| Naronapride (ATI-7505) | Renexxion | Phase 2b |
| M107 | Aclipse Therapeutics | Phase 2 |
| Real-World Evidence & Post-Market Surveillance | Enterra Medical | Post-Market |
| Astressin Platform | Sentia Medical Sciences | Pre-clinical |
| NEREUS™ (tradipitant) | Vanda Pharmaceuticals | Development |
| ABP-450 | AEON Biopharma | Research |